The management of sarcomas, a diverse group of cancers arising from connective tissues, presents significant challenges due to their heterogeneity and limited treatment options. Patient-derived sarcoma organoids (PDSOs) have emerged as a promising tool in the multimodal management of sarcomas, offering unprecedented opportunities for personalized medicine and improved treatment strategies. This review aims to explore the potential of PDSOs as a promising tool for multimodal management of sarcomas. We discuss the establishment and characterization of PDSOs, which realistically recapitulate the complexity and heterogeneity of the original tumor, providing a platform for genetic and molecular fidelity, histological resemblance, and functional characterization. Additionally, we discuss the applications of PDSOs in pathological and genetic evaluation, treatment screening and development, and personalized multimodal management. One significant advancement of PDSOs lies in their ability to guide personalized treatment decisions, enabling clinicians to assess the response and efficacy of different therapies in a patient-specific manner. Through continued research and development, PDSOs hold the potential to revolutionize sarcoma management and drive advancements in personalized medicine, biomarker discovery, preclinical modeling, and therapy optimization. The integration of PDSOs into clinical practice can ultimately improve patient outcomes and significantly impact the field of sarcoma treatment.
肉瘤是一类源于结缔组织的异质性恶性肿瘤，其管理因肿瘤异质性和治疗手段有限而面临重大挑战。患者来源肉瘤类器官作为一种新兴工具，为肉瘤的多模式管理提供了新途径，为个体化医疗和治疗策略优化带来了前所未有的机遇。本文旨在探讨患者来源肉瘤类器官作为肉瘤多模式管理工具的潜力。我们系统阐述了该类器官模型的建立与特征鉴定方法，其能真实再现原始肿瘤的复杂性与异质性，为遗传分子保真度研究、组织学相似性分析和功能表征提供了理想平台。同时，我们重点探讨了该类器官在病理遗传评估、治疗筛选开发及个体化多模式管理中的应用价值。该技术的重大进展在于能够指导个体化治疗决策，使临床医生能以患者特异性方式评估不同疗法的反应与疗效。通过持续研发，患者来源肉瘤类器官有望革新肉瘤诊疗模式，推动个体化医疗、生物标志物发现、临床前建模及治疗优化等领域的发展。将该技术整合到临床实践中，最终将改善患者预后并对肉瘤治疗领域产生深远影响。
Patient-Derived Organoids as a Promising Tool for Multimodal Management of Sarcomas
肿瘤(癌症)患者之家